You are here

Regeneron

Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval

Fierce Pharma

Thu, 12/1/22 - 07:11 pm

non-small cell lung cancer

Bristol Myers Squibb

UK regulators warn of ocular side effects after treatment with Sanofi's Dupixent

Fierce Pharma

Thu, 12/1/22 - 10:43 am

Regeneron, CytomX Ink Potentially $2B Bispecific Immunotherapy Deal

BioSpace

Thu, 11/17/22 - 12:05 pm

CytomX Therapeutics

drug development

AstraZeneca and Sanofi win big as Europe's human medicines committee endorses approvals, label expansions

Fierce Pharma

Mon, 11/14/22 - 07:10 pm

Dupixent nears EU approval for rare skin disease prurigo nodularis

Pharmaphorum

Mon, 11/14/22 - 10:52 am

prurigo nodularis

Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo

Endpoints

Wed, 11/9/22 - 10:38 am

non-small cell lung cancer

Amgen's Supreme Court bid answered in long-running Repatha patent feud against Sanofi, Regeneron

Fierce Pharma

Mon, 11/7/22 - 10:55 am

Insmed, Alnylam and others make Science's list of top 20 biopharma employers

Endpoints

Sun, 11/6/22 - 01:32 pm

Regeneron scratches NGF inhibitor and cat allergy therapy from pipeline

Fierce Biotech

Thu, 11/3/22 - 11:53 am

Regeneron, Bayer's Eylea nabs six months of pediatric exclusivity as competition waits to enter the market

Endpoints

Mon, 10/24/22 - 11:10 pm

pediatric exclusivity

Sanofi, Regeneron team with Broadway actor for digital severe asthma program

Medical Marketing and Media

Wed, 10/19/22 - 10:54 pm

pharma marketing

FDA Review: Phanes, Pfizer, GSK and More

BioSpace

Fri, 10/14/22 - 10:38 am

Eagle Pharmaceuticals

Galactin Therapeutics

Gilead Sciences

scPharmaceuticals

Regeneron secures priority review for Eylea's use in infant retinopathy

Fierce Pharma

Wed, 10/12/22 - 11:40 pm

retinopathy of prematurity

priority review

Dupixent Shows Promise as First Treatment for Childhood EoE

BioSpace

Wed, 10/12/22 - 10:33 am

clinical trials

eosinophilic esophagitis

The gloom deepens for biopharma stocks

EP Vantage

Mon, 10/10/22 - 06:54 pm

biopharma stocks

CRISPR Therapeutics

Intellia Therapeutics

Sarepta Therapeutics

FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis

Pharmaceutical Business Review

Thu, 09/29/22 - 10:05 am

prurigo nodularis

Biden admin says Supreme Court should reject Amgen's petition to take up Repatha patent case

Fierce Pharma

Thu, 09/22/22 - 11:14 pm

Intellia's gene editing therapies both post early successes as evidence grows for CRISPR potential

Fierce Biotech

Fri, 09/16/22 - 10:53 am

Intellia Therapeutics

ATTR amyloidosis

clinical trials

ESMO 2022 movers – KRAS backfires

EP Vantage

Thu, 09/15/22 - 10:12 am

KRAS inhibitors

Relay Therapeutics

Clovis Oncology

Ayala Pharmaceuticals

Mirati Therapeutics

Regeneron Highlights Plug-and-Play Oncology Strategy at ESMO

BioSpace

Mon, 09/12/22 - 11:32 pm

Pages